MicroRNA-876-5p represses the cell proliferation and invasion of colorectal cancer through suppressing YAP signalling via targeting RASAL2

Aberrant expression of microRNA-876-5p (miR-876-5p) is implicated in the progression of multiple human cancers. However, the potential role of miR-876-5p in colorectal cancer remains poorly understood. The purpose of the current study was to investigate the potential role of miR-876-5p in colorectal cancer. miR-876-5p expression was significantly downregulated in colorectal cancer tissues and cell lines compared with normal controls. Gain-of-function assays revealed that miR-876-5p overexpression effectively repressed the malignant behaviours of colorectal cancer cells, including cell proliferation, colony formation, and invasion. Bioinformatics analysis predicted that RAS protein activator like 2 (RASAL2), a potential oncogene for colorectal cancer, is a putative miR-876-5p target gene. A luciferase reporter assay confirmed that miR-876-5p directly binds to the 3′-untranslated region (UTR) of RASAL2. Furthermore, both RASAL2 messenger RNA (mRNA) and protein expression were negatively modulated by miR-876-5p in colorectal cancer cells. Notably, there was an inverse correlation between miR-876-5p and RASAL2 expression in colorectal cancer tissue specimens. Moreover, miR-876-5p was involved in regulating the activation of Yes-associated protein (YAP) signalling through inhibiting RASAL2. However, the miR-876-5p-mediated antitumour effect on colorectal cancer cells was partially reversed by restoring RASAL2 expression. Notably, miR-876-5p upregulation impeded the tumour growth of colorectal cancer cells in vivo in nude mice. Overall, these results demonstrated that miR-876-5p exerts an antitumour function in colorectal cancer by targeting RASAL2 to suppress YAP signalling activation. These findings highlight the importance of the miR-876-5p/RASAL2/YAP axis in colorectal cancer progression and suggest that miR-876-5p is a potential therapeutic target for treating colorectal cancer.     

出血坏死表型肝细胞癌病理特征及预后的前瞻性初步研究

目的:探讨出血坏死表型的肝细胞癌(HN-HCC)的病理特征及临床预后。方法:前瞻性入组67例手术与病理证实的HN-HCC患者,并以同期37例非HN-HCC(NHN-HCC)患者为对照。比较HN-HCC与NHN-HCC大体病理学差异;对HN-HCC标本的组织病理学以及Ki-67、缺氧诱生因子1α(HIF-1α)、cleaved-caspase-3的表达行多区域检测;检测HN-HCC标本碳酸酐酶IX(CA-IX)和E-钙黏蛋白的表达;比较HN-HCC患者与NHN-HCC患者术后生存率的差异。结果:HN-HCC与NHN-HCC呈现明显不同的大体病理形态。组织病理学观察与免疫组化检测显示,在HN-HCC瘤内不同区域,细胞分化程度有明显差异;Ki-67、cleaved-caspase-3、HIF-1α的表达量有明显差异(均P0.05)。在HN-HCC标本中,CA-IX阳性表达率为86.5%(58/67),E-钙黏蛋白为25.3%(17/67),且两者表达呈负相关(r=-2.601,P0.05)。与NHN-HCC患者比较,HN-HCC患者的1、3、5年总体生存率(71.9%、10.7%、2.8%vs.87.5%、35.6%、3.6%)与无瘤生存率(67.0%、15.4%、3.2%vs.81.2%、34.3%、4.0%)均明显降低(均P0.05)。结论:HCC合并出血坏死病理改变提示肿瘤有较强的瘤内异质性和侵袭转移潜能,患者预后不良。     

The vial kit formulation for preparation of no‐carrier‐added 131I‐MIBG

We have developed a new set of lyophilized kits, composed of 3 different kits, for the instant preparation of no‐carrier‐added ¹³¹I‐MIBG in the clinic. We here discussed the formulation of the kits, optimization of radiolabelling, quality control of radiolabeled ¹³¹I‐MIBG, and studies of animal biodistribution. The no‐carrier‐added (nca) ¹³¹I‐MIBG injection could be prepared within 30 minutes in the clinic with the help of the lyophilized kits. The radiochemical purity and specific activity (SA) could achieve above 98% and 6700 MBq/mg, respectively.     

《金匮要略》“纳药鼻中”之“药”考释

[目的] 探讨《金匮要略·痉湿暍病脉证并治第二》“纳药鼻中”之“药”所指的具体方药。[方法] 从历代注家注疏入手,对不同观点进行源流上的梳理。同时,通过文字学考证,对“药”字在古汉语中的含义展开探讨。[结果] 对于“纳药鼻中”之“药”,历代注家观点大致可归纳为三类,即随文注解、认为“药”为具有某些特性的药物、认为“药”为瓜蒂散或其类方,其中认为“纳瓜蒂于鼻中”的观点流传较广。通过文字学考证,“药”在楚方言中有指代“白芷”之意,“纳药鼻中”即是“纳白芷于鼻中”,白芷治疗鼻病也为历代医家所习用。[结论] “纳瓜蒂于鼻中”与“纳白芷于鼻中”两种观点都具有一定证据支持,但从文献学角度和仲景书体例而言,“纳药鼻中”原意应为“纳白芷于鼻中”。     

伤科黄水外敷在全膝关节置换术后的应用效果观察

目的：探讨伤科黄水在全膝关节置换术后的应用效果。方法：选择2020年1月至2021年3月我院收治的膝骨性关节炎行全膝关节置换术的患者134例,随机分为2组,每组各67例。对照组给予术后常规康复,观察组给予术后常规康复联合使用伤科黄水外敷。比较两组护理前后的膝关节活动度(ROM)、疼痛视觉模拟评分(VAS)、膝关节HSS评分、肿胀值、匹兹堡睡眠质量指数量表(PSQI)评分、深静脉血栓发生率。结果：干预后, 两组的ROM和HSS评分均较干预前升高(P<0.05),且干预后观察组的ROM和HSS评分均高于对照组(P<0.05);干预后,两组的VAS评分、PSQI评分、肿胀值均较干预前降低(P<0.05),且干预后观察组VAS评分、PSQI评分、肿胀值均低于对照组(P<0.05);观察组深静脉血栓发生率低于对照组(P<0.05)。结论：伤科黄水外敷可以改善全膝关节置换术后患者的膝关节功能,缓解肿痛,提高睡眠质量,降低深静脉血栓发生率。     

术前血小板/淋巴细胞比值与胰十二指肠切除术后静脉血栓栓塞症的发生及预后的关系

目的 探讨术前血小板/淋巴细胞比值（PLR）与胰十二指肠切除（PD）术后静脉血栓栓塞症（VTE）的发生及预后的关系。方法 回顾性分析2014年1月至2018年12月在新疆医科大学附属第一、第五医院行PD术的206例患者资料,比较VTE组及非VTE组患者在术前资料、手术因素、血常规、PLR方面的差异,绘制术前PLR预测术后VTE的受试者工作特征（ROC）曲线。根据PLR临界值进一步将VTE组分为高PLR亚组和低PLR亚组,分析两亚组在VTE血栓形成部位、术后生存时间方面有无差异。结果 PD术后发生VTE组（63例）和非VTE组（143例）在PLR上具有统计学差异（t=5.324,P<0.001）。PLR预测术后VTE的ROC曲线下面积（AUC）为0.853（95%CI 0.784~0.928）,敏感性为90.3%,特异性为75.0%,PLR临界值为244.54。高PLR亚组（n=30）术后双侧静脉血栓（BVT）12例、肺栓塞（PTE）13例,低PLR亚组（n=33）BVT 5例、PTE 6例,两亚组存在统计学差异（BVT：χ²=4.925,P=0.026;PTE：χ²=4.720,P=0.030）。高PLR亚组术后中位生存时间11个月（95%CI 10.238~11.762）,低PLR亚组为12个月（95%CI 10.530~13.470）,差异有统计学意义（χ²=5.909,P=0.015）。结论 术前PLR是PD术后发生VTE的独立危险因素,PLR值越大,术后发生静脉栓塞的风险越高,患者术后生存时间越短。根据术前PLR值早期干预具有VTE高风险的患者,可以延长患者PD术后生存时间。